The accompanying notes are an integral part of these unaudited consolidated
financial statements.
The accompanying notes are an integral part of these unaudited consolidated
financial statements.
The accompanying notes
are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated
financial statements.
The accompanying notes are an integral part of these unaudited consolidated
financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1 - Basis of Presentation
The accompanying consolidated balance sheet
as of December 31, 2016, the consolidated statements of operations and comprehensive income (loss) for the three months ended December
31, 2016 and 2015, changes in stockholders’ equity for the three months ended December 31, 2016 and cash flows for the three
months ended December 31, 2016 and 2015 of Dynasil Corporation of America and subsidiaries (the “Company”), and the
related information contained in these notes have been prepared by management and are unaudited. Xcede Technologies, Inc. (“Xcede”)
is a joint venture between Dynasil Biomedical and Mayo Clinic to spin out and separately fund the development of a tissue sealant
technology. As of December 31, 2016, Dynasil Biomedical owned 59% of Xcede’s stock and, as a result, Xcede is included in
the Company’s consolidated balance sheets, results of operations and cash flows. The remaining 41% of Xcede’s stock
owned by others and accounted for under the rules applicable to non-controlling interest. Certain prior year balances have been
reclassified to conform to the current year presentation. These reclassifications did not affect previously reported net income
or stockholders’ equity. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items)
necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally
accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative
of operating results for a full year.
The preparation of our unaudited consolidated
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the
reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included
in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed
or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto
included in the Company's September 30, 2016 Annual Report on Form 10-K previously filed by the Company with the Securities and
Exchange Commission.
The Company considers events or transactions
that have occurred after the unaudited consolidated balance sheet date of December 31, 2016, but prior to the filing of the unaudited
consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative
to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated
through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.
Note 2 – Recent Accounting Pronouncements
Effective October 1, 2016, the Company adopted
the guidance issued in Accounting Standards Update 2014-12,
Compensation—Stock Compensation (Topic 718) Accounting for
Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service
Period
(“ASU 2014-12”), which clarifies the proper method of accounting for share-based payments when the terms
of an award provide that a performance target could be achieved after the requisite service period. Under the new guidance, a performance
target that affects vesting and could be achieved after completion of the service period should be treated as a performance condition
under FASB Accounting Standards Codification (ASC) 718 and, as a result, should not be included in the estimation of the grant-date
fair value of the award. An entity should recognize compensation cost for the award when it becomes probable that the performance
target will be achieved. In the event that an entity determines that it is probable that a performance target will be achieved
before the end of the service period, the compensation cost of the award should be recognized prospectively over the remaining
service period. The adoption of this ASU did not have an impact on the Company’s financial statements.
Effective October 1, 2016, the Company adopted
the guidance issued in Accounting Standards Update 2015-01,
Income Statement - Extraordinary and Unusual Items (Subtopic 225-20):
Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items
(“ASU 2015-01”), which
eliminates the concept of extraordinary items in an entity’s income statement. Extraordinary classification outside of income
from continuing operations was previously considered only when evidence clearly supported its classification as an extraordinary
item. Extraordinary items were events and transactions that were distinguished by their unusual nature and by the infrequency of
their occurrence. The ASU eliminates the need to separately classify, present and disclose extraordinary events. The adoption of
this ASU did not have an impact on the Company’s financial statements.
Effective October 1, 2016, the Company adopted
the guidance issued in Accounting Standards Update 2015-16,
Business Combinations (Topic 805), Simplifying the Accounting for
Measurement-Period Adjustments
(“ASU No. 2015-16”), which requires that an acquirer recognize adjustments to provisional
amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined.
The acquirer needs to record, in the same period’s financial statements, the effect on earnings of changes in depreciation,
amortization or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting
had been completed at the acquisition date. In addition, an entity is required to present, separately on the face of the income
statement or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have
been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition
date. The adoption of this ASU did not have an impact on the Company’s financial statements.
Revenue from Contracts with Customers (Topic
606) Section A—Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and
Deferred Costs—Contracts with Customers (Subtopic 340-40).
In May 2014, the FASB issued ASU 2014-09,
Revenue from
Contracts with Customers
, which supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605),”
and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that
reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In March 2016, the
FASB issued ASU 2016-08,
Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross
versus Net)
, which clarifies gross versus net revenue reporting when another party is involved in the transaction. In April
2016, the FASB issued ASU 2016-10,
Identifying Performance Obligations and Licensing,
which amends the revenue guidance
on identifying performance obligations and accounting for licenses of intellectual property. There are two transition methods
available under the new standard, either cumulative effect or retrospective. The new guidance is effective for the Company beginning
in fiscal 2019. In May 2016, the FASB issued ASU 2016-12,
Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements
and Practical Expedients
, which clarifies the revenue guidance. In December 2016, the FASB issued ASU 2016-20,
Technical
Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,
which provides technical corrections and
improvements to Topic 606 and other Topics amended by ASU 2014-09. The Company is currently in the process of assessing the impact
of these ASUs on its consolidated financial statements.
Preparation of Financial Statements –
Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.
In
August 2014, the FASB issued ASU No. 2014-15, which states that under GAAP, continuation of a reporting entity as a going concern
is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. If
and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of
accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt
about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be
prepared under the going concern basis of accounting, but the amendments in this ASU should be followed to determine whether to
disclose information about the relevant conditions and events. The new guidance is effective for the Company’s annual reporting
for fiscal 2017, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is assessing the
impact of this ASU on its consolidated financial statements and plans to adopt it in the fourth quarter of fiscal year 2017.
Business Combinations (Topic 805): Clarifying
the Definition of a Business:
In January 2017, the FASB issued ASU 2017-01, which clarifies the definition of a business for
determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The guidance is
effective for the Company beginning October 1, 2018. The Company is currently in the process of assessing the impact of this ASU
on its consolidated financial statements.
Intangibles – Goodwill and Other (Topic
350): Simplifying the Test for Goodwill Impairment:
In January 2017, the FASB issued ASU 2017-04, which simplifies the test
for goodwill impairment. This new guidance is effective for the Company beginning in fiscal year 2021. The Company is currently
in the process of assessing the impact of this ASU on its consolidated financial statements.
Note 3 – Xcede Technologies, Inc.
Joint Venture
In October 2013, the Company, through its
subsidiary Dynasil Biomedical (“DBM”) formed Xcede, a joint venture with Mayo Clinic, in order to spin out and separately
fund the development of its hemostatic tissue sealant technology, which formerly comprised the majority of its expense within the
biomedical segment.
Beginning at its inception and through
November 2016, Xcede funded its pre-clinical research activities through the issuance of convertible notes bearing interest at
5% (“the Notes”) pursuant to a note purchase agreement dated October 2013 and most recently amended in November 2016
that provided for the issuance of up to $5.2 million in the aggregate principal amount of the Notes from external investors and
certain directors and officers of the Company. The Notes were convertible into equity of Xcede.
In November 2016, Dynasil committed to
invest $1.2 million of cash into Xcede over the following 18 months in exchange for Series B convertible preferred stock of Xcede
(“Series B Preferred”). The value of the Series B Preferred, as it is wholly owned by DBM, was eliminated in consolidation.
In conjunction with Dynasil’s committed investment, all $5.5 million in existing Notes and accrued interest were converted
into 5,394,120 shares of Series A convertible preferred stock of Xcede (“Series A Preferred”) at a 20% discount to
the price per share of the Series B Preferred, in accordance with the amended provisions of the Notes. The original conversion
terms of the Notes were amended to require conversion into Series A Preferred rather than the class of stock issued in conjunction
with the financing (Series B Preferred). Because the original conversion terms of the Notes were amended and as a result of assessing
the impact of the rights and features of the Note amendment and their effect on the value to the issuer and holders, the transaction
is recorded at fair value with a resulting gain on extinguishment of debt. Fair value was determined by management based on an
independent valuation using a market and income approach and an option pricing model to allocate value to the respective shares.
The fair value of the Series A Preferred was approximately $3.5 million on the date of issuance, as compared to the carrying value
of the convertible principal and accrued interest of $5.5 million, resulting in a gain of approximately $2.0 million. Due to the
related party nature of the transaction, this gain was recorded within the equity of Xcede. Of that $2.0 million, approximately
$1.7 million was attributed to DBM and eliminated in consolidation, and approximately $0.3 million was attributed to noncontrolling
interest.
Series A Preferred participants include
both outside investors (accounted for as noncontrolling interest) and DBM. The outside investors converted $3.1 million of Notes
and accrued interest into 3,055,551 shares of Series A Preferred. DBM converted the remaining $2.4 million of Notes and accrued
interest into 2,338,569 shares of Series A Preferred, the value of which is eliminated in consolidation.
Each share of Series A Preferred and Series
B Preferred (together “the Preferred Stock”) shall be convertible, at the option of the holder, into such number of
fully paid and non-assessable shares of Xcede common stock (“Common Stock”) as determined by dividing the original
issue price, as defined, by the conversion price in effect on the date of conversion, which is 1:1. Each holder of the Preferred
Stock shall have one vote for each share of Common Stock that the holder of the Preferred Stock would be entitled to receive upon
the conversion of the holder’s Preferred Stock into Common Stock. Upon any liquidation event, which includes certain change
of control events, following payment of pre-equity distributions, the remaining proceeds or net assets of Xcede shall be paid and
distributed in the following amounts and order of priority: (1) to satisfy the liquidation preference payment due to each holder
of Series B Preferred, (2) to satisfy the liquidation preference payment due to each holder of Series A Preferred, (3) payment
in full of any acquisition transaction payment, and (4) the remaining assets available to be distributed ratably among the holders
of the Common Stock. If a liquidation event were to occur, the Series A Preferred’s liquidation value would be $1.016 per
share and Series B Preferred’s liquidation value would be $1.27 per share. As of December 31, 2016, the liquidation value
of the Series B Preferred would be approximately $0.2 million and the Series A Preferred would be approximately $5.5 million, of
which $2.4 million is DBM’s portion and $3.1 million would be attributed to noncontrolling shareholders.
As of December 31, 2016, DBM owned approximately
59% of Xcede’s outstanding Common Stock and Preferred Stock and, as a result, Xcede is included in the Company’s consolidated
balance sheets, results of operations and cash flows. Due to the Series A Preferred having a liquidation preference and therefore
not representing a residual interest, cumulative net losses of Xcede are attributed only to common stockholders in accordance with
common stock ownership. Noncontrolling interest represents the value of the Series A Preferred and common stock not owned by DBM
plus 17% of cumulative losses of Xcede based on the 17% common stock ownership held by noncontrolling interests.
Due to the issuance of Preferred Stock,
DBM’s ownership percentage in Xcede decreased to less than 80%. Based on this ownership percentage, beginning in fiscal year
2017, Xcede will no longer be included in the Dynasil consolidated federal tax return and the Company will no longer be able to
offset taxable income or benefit from net operating losses and other tax attributes related to Xcede. (See Note 11 – Income
Taxes.)
As previously disclosed, in January 2016,
Xcede announced that it had signed three agreements with Cook Biotech Inc. of West Lafayette, Indiana (“Cook”), including
a Development Agreement, a License Agreement and a Supply Agreement, in connection with the development, regulatory approval and
production of Xcede’s resorbable hemostatic patch (“Xcede’s Patch”). In November 2016, Xcede entered into
another Services Agreement, a Secured Promissory Note, a Loan Agreement, a Security Agreement and an Intellectual Property Security
Agreement (collectively the “Note Agreement”) with Cook, in which Cook committed to fund the pre-clinical testing of,
and subject to the receipt of applicable regulatory approvals to initiate first in human clinical trials for, the Xcede Patch. Under
the terms of the Note Agreement, in exchange for the services performed by Cook, Xcede has committed to a multiple draw credit
facility in the aggregate amount not to exceed $1.5 million. Three draws of principal will be available, each in the amount
of $500,000, upon satisfaction of conditions identified in the Note Agreement. The principal amounts outstanding bear interest
at a fixed rate of 2% and are secured by all the rights of Xcede under the Development Agreement, Supply Agreement, and License
Agreement, all the rights to the data and work product arising from the clinical trial being performed under the Services Agreement,
all regulatory approvals for the Xcede Patch, all patent and patent applications owned or controlled by Xcede, and all trademark
and service mark registrations and applications. The outstanding principal and unpaid interest are due and payable in full
at the earlier of closing of an acquisition transaction or December 31, 2025. Xcede will recognize research and development expense
as the related services are performed by Cook. There was approximately $38,000 of research and development expense recognized during
the three months ended December 31, 2016.
Note 4 - Inventories
Inventories, net of reserves, consists of the following:
|
|
December 31,
|
|
|
September 30,
|
|
|
|
2016
|
|
|
2016
|
|
Raw Materials
|
|
$
|
2,024,000
|
|
|
$
|
1,938,000
|
|
Work-in-Process
|
|
|
690,000
|
|
|
|
834,000
|
|
Finished Goods
|
|
|
1,202,000
|
|
|
|
954,000
|
|
|
|
$
|
3,916,000
|
|
|
$
|
3,726,000
|
|
Note 5 – Intangible Assets
Intangible assets at December 31, 2016 and September 30, 2016 consist
of the following:
|
|
Useful
|
|
Gross
|
|
|
Accumulated
|
|
|
|
|
December 31, 2016
|
|
Life (years)
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
Acquired Customer Base
|
|
5 to 15
|
|
$
|
683,000
|
|
|
$
|
467,000
|
|
|
$
|
216,000
|
|
Know How
|
|
15
|
|
|
512,000
|
|
|
|
290,000
|
|
|
|
222,000
|
|
Trade Names
|
|
Indefinite
|
|
|
258,000
|
|
|
|
-
|
|
|
|
258,000
|
|
Patents
|
|
20
|
|
|
345,000
|
|
|
|
8,000
|
|
|
|
337,000
|
|
Biomedical Technologies
|
|
5
|
|
|
260,000
|
|
|
|
260,000
|
|
|
|
-
|
|
|
|
|
|
$
|
2,058,000
|
|
|
$
|
1,025,000
|
|
|
$
|
1,033,000
|
|
|
|
Useful
|
|
Gross
|
|
|
Accumulated
|
|
|
|
|
September 30, 2016
|
|
Life (years)
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
Acquired Customer Base
|
|
5 to 15
|
|
$
|
718,000
|
|
|
$
|
473,000
|
|
|
$
|
245,000
|
|
Know How
|
|
15
|
|
|
512,000
|
|
|
|
282,000
|
|
|
|
230,000
|
|
Trade Names
|
|
Indefinite
|
|
|
272,000
|
|
|
|
-
|
|
|
|
272,000
|
|
Patents
|
|
20
|
|
|
326,000
|
|
|
|
6,000
|
|
|
|
320,000
|
|
Biomedical Technologies
|
|
5
|
|
|
260,000
|
|
|
|
260,000
|
|
|
|
-
|
|
|
|
|
|
$
|
2,088,000
|
|
|
$
|
1,021,000
|
|
|
$
|
1,067,000
|
|
Amortization expense for the three months ended December 31, 2016
and 2015 was $26,000 and $44,000, respectively.
Estimated amortization expense for each of the next five fiscal
years and thereafter is as follows:
|
|
2017 (9 months)
|
|
|
2018
|
|
|
2019
|
|
|
2020
|
|
|
2021
|
|
|
Thereafter
|
|
|
Total
|
|
Acquired Customer Base
|
|
$
|
60,000
|
|
|
$
|
80,000
|
|
|
$
|
76,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
216,000
|
|
Know How
|
|
|
26,000
|
|
|
|
34,000
|
|
|
|
34,000
|
|
|
|
34,000
|
|
|
|
34,000
|
|
|
|
60,000
|
|
|
|
222,000
|
|
Patents
|
|
|
6,000
|
|
|
|
9,000
|
|
|
|
9,000
|
|
|
|
9,000
|
|
|
|
9,000
|
|
|
|
79,000
|
|
|
|
121,000
|
|
|
|
$
|
92,000
|
|
|
$
|
123,000
|
|
|
$
|
119,000
|
|
|
$
|
43,000
|
|
|
$
|
43,000
|
|
|
$
|
139,000
|
|
|
$
|
559,000
|
|
As of December 31, 2016, Xcede had $216,000 in patents that have
not been granted, therefore, the amortization related to these patents is not included in the five-year amortization table above.
The Company continually assesses whether events or changes in circumstances
have occurred that may warrant revision of the estimated useful lives of its long-lived assets or whether the remaining balances
of those assets should be evaluated for possible impairment. There were no changes, aside from foreign exchange rate fluctuations,
in the carrying value of long-lived assets, during the three months ended December 31, 2016.
Note 6 – Goodwill
Goodwill is subject to an annual impairment
test. The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests. These
include:
|
·
|
A significant adverse long term outlook
for any of its industries;
|
|
·
|
An adverse finding or rejection from a
regulatory body involved in new product regulatory approvals;
|
|
·
|
Failure of an anticipated commercialization
of a product or product line;
|
|
·
|
Unanticipated competition or the introduction
of a disruptive technology;
|
|
·
|
The testing for recoverability under the Impairment or Disposal of
Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit;
|
|
·
|
A loss of key personnel; and
|
|
·
|
An expectation that a reporting unit carrying goodwill, or a significant
portion of a reporting unit, will be sold or otherwise disposed of.
|
There were no changes, aside from foreign exchange
rate fluctuations, in the carrying value of goodwill, during the three months ended December 31, 2016.
Note 7 – Debt
Senior Debt
The Bank Loan Agreement between the Company
and Middlesex Savings Bank was amended on December 2, 2016 to permit the Company to invest up to $1.2 million in its Xcede Technologies
subsidiary during the period from the quarter ended December 31, 2016 through the quarter ending September 30, 2018.
Subordinated Debt
On December 15, 2016, the Company amended the
Note Purchase Agreement with Massachusetts Capital Resource Company to reinstate the interest only payment requirements of the
loan and defer principal repayment requirements to November 30, 2017. Such amendment also extended the maturity date from July
31, 2018 to July 31, 2019.
Subsidiary Debt
In November 2016, the Xcede convertible
notes along with related accrued interest were converted into 5,394,120 shares of Xcede’s Series A preferred stock. See
Note 3 – Xcede Technologies, Inc. Joint Venture.
Note 8 – Earnings (Loss) Per Common
Share
Basic earnings (loss) per common share is computed
by dividing the net income or loss attributable to common shares by the weighted average number of common shares outstanding. Diluted
earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible
preferred stock and other potential dilutive common shares outstanding during the periods.
For purposes of computing diluted earnings
per share for the three months ended December 31, 2016 and 2015, no common stock options were included in the calculation of dilutive
shares as all of the 123,147 and 58,212 common stock options outstanding, respectively, had exercise prices above the applicable
quarterly average market price per share and their inclusion would be anti-dilutive.
For the three months ended December 31, 2016,
90,000 shares of restricted common stock were excluded from the calculation of dilutive shares, as the effect of their inclusion
would be anti-dilutive. For the three months ended December 31, 2015, 27,437 restricted common stock were included in the denominator
used to calculate diluted earnings per share.
The computation of the weighted shares outstanding for the three
months ended December 31 is as follows:
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
Weighted average shares outstanding
|
|
|
|
|
|
|
|
|
Basic
|
|
|
16,808,729
|
|
|
|
16,551,197
|
|
Effect of dilutive securities
|
|
|
|
|
|
|
|
|
Stock Options
|
|
|
-
|
|
|
|
-
|
|
Restricted Stock
|
|
|
-
|
|
|
|
27,437
|
|
Dilutive Average Shares Outstanding
|
|
|
16,808,729
|
|
|
|
16,578,634
|
|
Note 9 - Stock Based Compensation
The fair value of the stock options granted
is estimated at the date of grant using the Black-Scholes option pricing model.
The expected volatility was determined with
reference to the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and
employee termination within the valuation model. The expected term of options granted represents the period of time that the options
granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based
on the U.S. Treasury rate in effect at the time of grant. The dividend yield is expected to be zero because historically the Company
has not paid dividends on common stock.
The Company’s Xcede joint venture adopted
an Equity Incentive Plan in 2013 which provides for, among other incentives, the granting of options to purchase shares in Xcede’s
common stock to officers, directors, employees and consultants. The options granted generally vest over a three year period. The
fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model using assumptions
generally consistent with those used for Company stock options. Because Xcede is not publicly traded, the expected volatility is
estimated with reference to the average historical volatility of a group of publicly traded companies that are believed to have
similar characteristics to Xcede.
Stock compensation expense for the three months ended December 31,
2016 and 2015 is as follows:
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
Stock Compensation Expense
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
Stock Grants
|
|
$
|
39,000
|
|
|
$
|
83,000
|
|
Restricted Stock Grants
|
|
|
13,000
|
|
|
|
8,000
|
|
Option Grants
|
|
|
12,000
|
|
|
|
6,000
|
|
Employee Stock Purchase Plan
|
|
|
1,000
|
|
|
|
1,000
|
|
Subsidiary Option Grants
|
|
|
24,000
|
|
|
|
21,000
|
|
Total
|
|
$
|
89,000
|
|
|
$
|
119,000
|
|
At December 31, 2016, there was approximately
$140,000 in unrecognized stock compensation cost for Dynasil, which is expected to be recognized over a weighted average period
of fourteen months.
Restricted Stock Grants
A summary of restricted stock activity for
the three months ended December 31, 2016 is presented below:
Restricted Stock Activity for the Three Months ended
December 31, 2016
|
|
Shares
|
|
|
Weighted-Average
Grant-Date Fair Value
|
|
Nonvested at September 30, 2016
|
|
|
100,000
|
|
|
$
|
1.73
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
Vested
|
|
|
(10,000
|
)
|
|
$
|
1.70
|
|
Cancelled
|
|
|
-
|
|
|
|
-
|
|
Nonvested and expected to vest at December 31, 2016
|
|
|
90,000
|
|
|
$
|
1.73
|
|
Stock Option Grants
During the three months ended December 31,
2016, no Dynasil stock options were granted. A summary of stock option activity for the three months ended December 31, 2016 is
presented below:
|
|
Options
Outstanding
|
|
|
Weighted Average
Exercise Price per
Share
|
|
|
Weighted Average
Remain Contractual
Term (in Years)
|
|
Balance at September 30, 2016
|
|
|
123,147
|
|
|
$
|
2.30
|
|
|
|
1.69
|
|
Outstanding and exercisable at September 30, 2016
|
|
|
123,147
|
|
|
$
|
2.30
|
|
|
|
1.69
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Cancelled
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Balance at December 31, 2016
|
|
|
123,147
|
|
|
$
|
2.30
|
|
|
|
1.43
|
|
Outstanding and exercisable at December 31, 2016
|
|
|
123,147
|
|
|
$
|
2.30
|
|
|
|
1.43
|
|
Subsidiary Stock Option Grants
During the three months ended December 31,
2016, 428,000 Xcede stock options were granted at an exercise price of $1.00 per share. Of the stock options granted, 228,000 options
were given to satisfy deferred compensation in the amount of $75,000 and vested immediately. The remaining 200,000 stock options
granted during the three months ended December 31, 2016 vest over the next three years and expire ten years from the grant date.
These options were valued using the Black-Scholes option pricing model and the assumptions for that were as follows:
Expected term in years
|
|
10 years
|
|
Risk-free interest rate
|
|
|
2.37
|
%
|
Expected volatility
|
|
|
83.12
|
%
|
Expected dividend yield
|
|
|
0.00
|
%
|
A summary of Xcede stock option activity for
the three months ended December 31, 2016 is presented below:
|
|
Options
Outstanding
|
|
|
Weighted Average
Exercise Price per
Share
|
|
|
Weighted Average
Remain Contractual
Term (in Years)
|
|
Balance at September 30, 2016
|
|
|
613,653
|
|
|
|
1.00
|
|
|
|
8.35
|
|
Outstanding and exercisable at September 30, 2016
|
|
|
320,586
|
|
|
|
1.00
|
|
|
|
8.01
|
|
Granted
|
|
|
428,000
|
|
|
|
1.00
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Cancelled
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Balance at December 31, 2016
|
|
|
1,041,653
|
|
|
|
1.00
|
|
|
|
8.84
|
|
Outstanding and exercisable at December 31, 2016
|
|
|
629,126
|
|
|
|
1.00
|
|
|
|
8.74
|
|
At December 31, 2016, the Company’s Xcede
joint venture had $163,000 of unrecognized stock compensation expense associated with stock options expected to be recognized over
a weighted average period of seventeen months.
Note 10 – Segment, Customer and Geographical
Reporting
Segment Financial Information
Dynasil reports three reportable segments:
contract research (“Contract Research”), optics (“Optics”) and biomedical (“Biomedical”). Within
these segments, there is a segregation of operating segments based upon the organizational structure used to evaluate performance
and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with
that structure. The Optics segment aggregates four operating segments – Dynasil Fused Silica, Optometrics, Hilger Crystals,
and Evaporated Metal Films – that manufacture commercial products, including optical crystals for sensing in the security
and medical imaging markets, as well as optical components, optical coatings and optical materials for scientific instrumentation
and other applications. The Contract Research segment is one of the largest small business participants in U.S. government-funded
research. The Biomedical segment consists of a single operating segment, Dynasil Biomedical Corporation (“Dynasil Biomedical”),
a medical technology incubator which owns rights to certain early stage medical technologies. Dynasil Biomedical holds common and
preferred stock in the Xcede joint venture which is developing a tissue sealant technology and currently has no other operations.
The Company’s segment information for
the three months ended December 31, 2016 and 2015 is summarized below:
Results of Operations for the Three Months Ended December 31,
|
2016
|
|
|
Optics
|
|
|
Contract
Research
|
|
|
Biomedical
|
|
|
Total
|
|
Revenue
|
|
$
|
4,405,000
|
|
|
$
|
4,738,000
|
|
|
$
|
-
|
|
|
$
|
9,143,000
|
|
Gross profit
|
|
|
1,574,000
|
|
|
|
1,951,000
|
|
|
|
-
|
|
|
|
3,525,000
|
|
GM %
|
|
|
36
|
%
|
|
|
41
|
%
|
|
|
-
|
|
|
|
39
|
%
|
SG&A
|
|
|
1,328,000
|
|
|
|
1,740,000
|
|
|
|
381,000
|
|
|
|
3,449,000
|
|
Operating income (loss)
|
|
|
246,000
|
|
|
|
211,000
|
|
|
|
(381,000
|
)
|
|
|
76,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
234,000
|
|
|
|
74,000
|
|
|
|
3,000
|
|
|
|
311,000
|
|
Capital expenditures
|
|
|
91,000
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
111,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangibles, net
|
|
|
474,000
|
|
|
|
222,000
|
|
|
|
337,000
|
|
|
|
1,033,000
|
|
Goodwill
|
|
|
883,000
|
|
|
|
4,939,000
|
|
|
|
-
|
|
|
|
5,822,000
|
|
Total assets
|
|
$
|
18,785,000
|
|
|
$
|
8,407,000
|
|
|
$
|
1,060,000
|
|
|
$
|
28,252,000
|
|
Results of Operations for the Three Months Ended December 31,
|
2015
|
|
|
Optics
|
|
|
Contract
Research
|
|
|
Biomedical
|
|
|
Total
|
|
Revenue
|
|
$
|
6,214,000
|
|
|
$
|
4,990,000
|
|
|
$
|
-
|
|
|
$
|
11,204,000
|
|
Gross profit
|
|
|
2,110,000
|
|
|
|
1,855,000
|
|
|
|
-
|
|
|
|
3,965,000
|
|
GM %
|
|
|
34
|
%
|
|
|
37
|
%
|
|
|
-
|
|
|
|
35
|
%
|
SG&A
|
|
|
1,751,000
|
|
|
|
1,706,000
|
|
|
|
348,000
|
|
|
|
3,805,000
|
|
Gain on sale of assets
|
|
|
4,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,000
|
|
Operating income (loss)
|
|
|
363,000
|
|
|
|
149,000
|
|
|
|
(348,000
|
)
|
|
|
164,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
228,000
|
|
|
|
80,000
|
|
|
|
17,000
|
|
|
|
325,000
|
|
Capital expenditures
|
|
|
565,000
|
|
|
|
7,000
|
|
|
|
31,000
|
|
|
|
603,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangibles, net
|
|
|
644,000
|
|
|
|
256,000
|
|
|
|
297,000
|
|
|
|
1,197,000
|
|
Goodwill
|
|
|
1,155,000
|
|
|
|
4,939,000
|
|
|
|
-
|
|
|
|
6,094,000
|
|
Total assets
|
|
$
|
16,506,000
|
|
|
$
|
8,273,000
|
|
|
$
|
857,000
|
|
|
$
|
25,636,000
|
|
Customer Financial Information
For the three months ended December 31, 2016,
no customer in the Optics segment represented more than 10% of the total segment revenue. For the three months ended December 31,
2015, one customer in the Optics segment represented more than 10% of the total segment revenue.
For the three months ended December 31, 2016,
three customers of the Contract Research segment, all various agencies of the U.S. Government, each represented more than 10% of
the total segment revenue. For the three months ended December 31, 2015, five customers of the Contract Research segment, all various
agencies of the U.S. Government, each represented more than 10% of the total segment revenue.
Geographic Financial Information
Revenue by geographic location in total and
as a percentage of total revenue, for the three months ended December 31, 2016 and 2015 are as follows:
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
Geographic Location
|
|
Revenue
|
|
|
% of Total
|
|
|
Revenue
|
|
|
% of Total
|
|
United States
|
|
$
|
7,189,000
|
|
|
|
79
|
%
|
|
$
|
8,235,000
|
|
|
|
74
|
%
|
Europe
|
|
|
1,086,000
|
|
|
|
12
|
%
|
|
|
2,041,000
|
|
|
|
18
|
%
|
Other
|
|
|
868,000
|
|
|
|
9
|
%
|
|
|
928,000
|
|
|
|
8
|
%
|
|
|
$
|
9,143,000
|
|
|
|
100
|
%
|
|
$
|
11,204,000
|
|
|
|
100
|
%
|
Note 11 - Income Taxes
The Company uses the asset and liability approach
to account for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between
the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and
net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using
the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based
on tax rates, and tax laws, in the respective tax jurisdiction then in effect.
Dynasil Corporation of America and its
wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns. The Company’s
U.K. subsidiary files tax returns in the U.K. Prior to November 18, 2016, the Company’s subsidiary, Xcede was included
in the federal and state tax returns filed by Dynasil. As of November 18, 2016, Dynasil’s ownership in Xcede was
reduced to approximately 59%. As a result, Xcede will no longer be included in Dynasil’s federal consolidated
tax return and will file a separate federal return. Xcede will continue to be included in the Dynasil consolidated state
tax filings pursuant to the respective state tax requirements.
In assessing the ability to realize the net
deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing
taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more
likely than not that some portion or all of the net deferred tax assets will not be realized.
As a result of
Xcede’s de-consolidation from the Company’s federal tax returns, the Company will no longer be able to offset
taxable income with Xcede’s current or cumulative operating losses. Upon review of relevant criteria for the new
Dynasil federal consolidated group, it was determined that it is more likely than not that the federal, deferred tax assets
of the new Dynasil federal consolidated group will be realized based upon positive earnings history and expected future
profits of the group. As a result, the federal deferred tax asset valuation allowance associated with the Dynasil
federal consolidated group has been reversed resulting in an income tax benefit in the amount of $2.7 million during the
quarter ending December 31, 2016. Going forward, as the company records income, it will be able to utilize the NOLs (net
operating losses) within its deferred tax assets. Based upon the Company’s recent losses and uncertainty of future
profits, the Company has determined that the uncertainty regarding the realization of the Company’s state and separate
Xcede deferred tax assets is sufficient to warrant the continued need for a valuation allowance against these deferred tax
assets.
The Company applies the authoritative provisions
related to accounting for uncertainty in income taxes. As required by these provisions, the Company recognizes the financial
statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the
position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial
statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with
the relevant tax authority. As of December 31, 2016 and September 30, 2016, the Company has no liabilities for uncertain tax
positions. Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense
in the accompanying consolidated statement of operations. As of December 31, 2016 and September 30, 2016, the Company had
no accrued interest or penalties related to uncertain tax positions. The Company currently has no federal or state tax examinations
in progress.
The results for the three months ending December
31, 2016 result in an overall effective rate for the quarter of 679% mainly driven by the tax benefit of $2.7 million recorded
for the release of the valuation allowance. The effective tax rates excluding the impact of the valuation allowance were (25%)
and 34% for the three months ended December 31, 2016 and 2015, respectively. The rates differ from the U.S. federal statutory
income tax rate of 34% primarily due to a full valuation allowance against certain U.S. deferred tax assets of the Company.
The Company files its tax returns as prescribed
by the tax laws of the jurisdictions in which it operates. The Company’s tax filings for federal and state jurisdictions
for the tax years beginning with 2013 are still subject to examination.
Note 12 – Subsequent Events
The Company has evaluated subsequent events
through the date the financial statements were released.